Propagative α-synuclein seeds as serum biomarkers for synucleinopathies.

Okuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno SI, Imamichi-Tatano Y, Kimura H, Kakuta S, Kondo A, Fukuhara T, Li Y, Funayama M, Saiki S, Taniguchi D, Tsunemi T, McIntyre D, Gérardy JJ, Mittelbronn M, Kruger R, Uchiyama Y, Nukina N, Hattori N. · 2023

Read Propagative α-synuclein seeds as serum biomarkers for synucleinopathies. by Okuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno SI, Imamichi-Tatano Y, Kimura H, Kakuta S, Kondo A, Fukuhara T, Li Y, Funayama M, Saiki S, Taniguchi D, Tsunemi T, McIntyre D, Gérardy JJ, Mittelbronn M, Kruger R, Uchiyama Y, Nukina N, Hattori N. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc10287557.txt.

Introduction

Okuzumi and a large team report that seeds of alpha-synuclein protein in blood serum can serve as markers for a family of brain diseases, in a 2023 study. These diseases, called synucleinopathies, include Parkinson's disease and dementia with Lewy bodies. In each, alpha-synuclein folds wrongly and spreads through the brain in a seed-like way.

The team amplified those seeds from blood samples and read their shapes. Different diseases left distinct seed signatures that matched the clinical diagnosis. A blood test of this kind could ease diagnosis of diseases now confirmed mainly after death.

Catalog record

CREATOROkuzumi A, Hatano T, Matsumoto G, Nojiri S, Ueno SI, Imamichi-Tatano Y, Kimura H, Kakuta S, Kondo A, Fukuhara T, Li Y, Funayama M, Saiki S, Taniguchi D, Tsunemi T, McIntyre D, Gérardy JJ, Mittelbronn M, Kruger R, Uchiyama Y, Nukina N, Hattori N.
YEAR2023
COLLECTIONPAPERS
FORMATTXT
FILE SIZE78 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC10287557

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Propagative α-synuclein seeds as serum biomarkers for synucleinopathies By Ayami Okuzumi, Taku Hatano, Gen Matsumoto, Shuko Nojiri, Shin-ichi Ueno, Yoko Imamichi-Tatano, Haruka Kimura, Soichiro Kakuta, Akihide Kondo, Takeshi Fukuhara, Yuanzhe Li, Manabu Funayama Published in: Nature Medicine DOI: 10.1038/s41591-023-02358-9 ABSTRACT Abnormal α-synuclein aggregation is a key pathological feature of a group of neurodegenerative diseases known as synucleinopathies, which include Parkinson’s disease (PD), dementia with Lewy bodies and multiple system atrophy (MSA). The pathogenic β-sheet seed conformation of α-synuclein is found in various tissues, suggesting potential as a biomarker, but few studies have been able to reliably detect these seeds in serum samples. In this study, we developed a modified assay system, called immunoprecipitation-based real-time quaking-induced conversion (IP/RT-QuIC), which enables the detection of pathogenic α-synuclein seeds in the serum of individuals with synucleinopathies. In our internal first and second cohorts, IP/RT-QuIC showed high diagnostic performance for differentiating PD versus controls (area under the curve (AUC): 0.96 (95% confidence interval (CI) 0.95–0.99)/AUC: 0.93 (95% CI 0.84–1.00)) and MSA versus controls (AUC: 0.64 (95% CI 0.49–0.79)/AUC: 0.73 (95% CI 0.49–0.98)). IP/RT-QuIC also showed high diagnostic performance in differentiating individuals with PD (AUC: 0.86 (95% CI 0.74–0.99)) and MSA (AUC: 0.80 (95% CI 0.65–0.97)) from controls in a blinded external cohort. Notably, amplified seeds maintained disease-specific properties, allowing the differentiation of samples from individuals with PD versus MSA. In summary, here we present a novel platform that may allow the detection of individuals with synucleinopathies using serum samples. MAIN Synucleinopathies, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB) and multiple system atrophy (MSA), are neurodegenerative disorders characterized by the abnormal aggregation of α-synuclein1–4. Additionally, rapid eye movement sleep behavior disorder (RBD) is a prodromal symptom of synucleinopathy5. In the pathologies of synucleinopathy, α-synuclein misfolding and aggregation involve a mechanism of seeding, in which initial seeds of α-synuclein, known as fibrils, recruit soluble monomers that form visible aggregates2,6 such as Lewy bodies (LB), a histopathological hallmark of PD, or neuronal cytoplasmic inclusions and oligodendroglial cytoplasmic inclusions in MSA7,8. Furthermore, abnormal α-synuclein aggregations are observed in systemic autonomic neurons in patients with synucleinopathy. Thus, it is possible that α-synuclein fibrils exist in the intricate systemic network, including the nervous, lymphatic and vascular systems9. Several studies revealed increased α-synuclein in the sera of patients with PD compared to healthy controls by ELISA, immunomagnetic reduction or electrochemiluminescence immunoassay10–13. Aptamer DNA-PAINT combined with single-aggregate confocal fluorescence methods revealed that some of the serum α-synucleins have abnormal β-sheet structures14. These findings suggest that α-synuclein fibrils in the serum of patients with synucleinopathies might be present in the blood, although these assays have not been available as diagnostic biomarkers of synucleinopathies. Synucleinopathy-specific α-synuclein fibrils were detected in cerebrospinal fluid (CSF)1,15–20, plasma neuron-derived exosomes21, saliva gland22, skin23,24 and olfactory mucosa25–27 by the amplification of abnormal α-synuclein aggregation using real-time quaking-induced conversion (RT-QuIC) assays, which takes advantage of the seeding properties to amplify small quantities of seeds. In this study, we developed a modified RT-QuIC assay combined with immunoprecipitation (IP) to concentrate α-synuclein seeds from serum: the IP-based RT-QuIC (IP/RT-QuIC) assay. We validated the IP/RT-QuIC usefulness as a diagnostic marker of synucleinopathies and propose here that the fibril morphology of products derived from IP/RT-QuIC of serum α-synuclein seeds in patients with synucleinopathies could discriminate among PD, DLB and MSA. We detected the serum α-synuclein seeds by IP/RT-QuIC in synucleinopathies and found the existence of the different conformational strains in the serum of patients with PD, DLB and MSA. RESULTS Participants The sera from 270 patients with synucleinopathy (221 PD, 39 MSA and 10 DLB), 9 patients with RBD (longitudinal IP/RT-QuIC was conducted for 3 of them), 128 non-neurodegenerative controls, 30 patients with progressive supranuclear palsy (PSP), 25 patients with Alzheimer’s disease (AD) and 17 patients with Parkin-linked PD (PRKN) were analyzed. The second internal cohort, which was recruited in our previous metabolomics investigation28, included 40 patients with synucleinopathy (34 PD and 6 MSA) and 9 non-neurodegenerative controls. We also analyzed an external cohort including a blinded analysis of 35 participants with synucleinopathies (20 PD and 15 MSA), 20 non-neurodegenerative controls and six patients with tauopathy as non-synucleinopathy controls. We additionally analyzed sera collected from internal and external cohorts of seven patients with pathologically confirmed synucleinopathies (three PD with dementia (PDD), three MSA from the internal cohort and one PDD from the external cohort), two pathologically verified patients with tauopathies as non-synucleinopathy controls (external cohort) and three age-matched controls (internal cohort). These patients’ clinical data are shown in Table 1 and Extended Data Table 1. In this study, sex and/or gender data were determined and assigned based on medical records.Table 1Characteristics of the study participantsAge (years), mean (s.d.)Men, n (%)Hoehn–Yahr stage, mean (s.d.)UPDRS-III, mean (s.d.)Disease duration (years), mean (s.d.)PD (n = 221)66 (10)98 (44)2.1 (1.0)13 (10)6.9 (5.8)MSA (n = 39)64 (8.5)15 (38)2.9 (1.3)35 (20)3.2 (2.3)DLB (n = 10)76 (5.3)6 (60)2.1 (0.6)19 (9.4)5.4 (3.6)RBD (n = 9)73 (6.2)4 (44)NA3 (7.5)8.8 (7.4)PSP (n = 30)72 (9.7)13 (43)3.5 (1.1)44 (21)4.7 (2.5)AD (n = 25)75 (9.0)10 (40)NANANAPRKN (n = 17)52 (18)6 (35)2.3 (0.7)20 (21)23 (12)Controls (n = 128)64 (15)61 (47)NANANANA, not applicable.Table 2Serum α-synuclein IP/RT-QuIC results and α-synuclein IP/RT-QuIC assay characteristics per diagnosisDiagnosisnIP/RT-QuIC results +/−Positive resultsSynucleinopathies PD221210/1195% MSA3925/1464% DLB109/190% RBD94/544%Non-synucleinopathies PSP301/293% AD254/2116% PRKN170/170%Controls12811/1178.5%Data are presented as numbers. n, number of participants who received IP/RT-QuIC. Detection of α-synuclein seeds in serum We examined the sensitivity to detect small amounts of α-synuclein seeds with parameters of IP/RT-QuIC assay. The time to threshold (T1/2 and Tmax) or area under the curve (AUC) depended on the initial α-synuclein seed concentration. We revealed that IP/RT-QuIC would detect a concentration of 1,000 pg ml−1 or higher. However, the substrate lot was critical because the unsuitable α-synuclein recombinant protein might be self-aggregated (false positive) or fail to convert to seed (false negative). The repetitive examinations concluded the detection limit as 1,000 pg ml−1. We defined the forming rate as the rate of aggregate formation that was determined as a slope of the tangent line at the inflection point of the sigmoid curve of the IP/RT-QuIC. The forming rates did not depend on the concentration (Supplementary Fig. 1). Next, we investigated the serum using IP/RT-QuIC (designated as serum IP/RT-QuIC) and identified α-synuclein seeds in synucleinopathy (Table 2 and Extended Data Table 4). Positive results for serum IP/RT-QuIC for patients with PD in the first, second and external cohorts were 210/221 (95%), 34/34 (100%) and 15/20 (75%), respectively (Table 2 and Extended Data Table 4). Negative results were found in 31 of 279 patients with synucleinopathy in the first cohort (11/221 PD, 14/39 MSA, 1/10 DLB and 5/9 RBD; Table 2 and Extended Data Table 3); 2 of 40 patients in the second internal cohort (0/34 PD and 2/6 MSA); and 12 of 35 patients in the external cohort (5/20 PD and 7/15 MSA) (Extended Data Table 4a,b). Results of the assay reproducibility analysis are provided in the Supplementary Methods (Supplementary Tables 1–5). Seventeen of 26 patients with MSA parkinsonian variant (MSA-P) and eight of 13 patients with MSA cerebellar variant (MSA-C) were positive (Supplementary Table 6). Positive results were found in five of 55 non-synucleinopathy patients (1/30 PSP and 4/25 AD) and 11 of 128 controls. The average age of the 11 control cases with

Read the complete text